Although the immediate market response was negative, most pharmaceutical stocks recovered after Wall Street analysts ...

BMO Capital cut Terns Pharmaceuticals' price target from $26 to $15, citing costlier capital conditions despite maintaining ...

Pharmaceutical stocks, including Pfizer (NYSE: PFE ... rebounded after Wall Street analysts highlighted the significant legal challenges the order would face. The pharmaceutical industry has ...

Shares of U.S. drugmakers rebounded on Monday after an initial selloff as analysts said that President Donald Trump's ...

positioning it well for future growth despite recent market challenges. The legal battle began in 2020 when Pfizer accused SK bioscience of infringing on the composition patent of its own vaccine ...

According to InvestingPro data, the company faces significant financial challenges ... ITIL agreed to cover a transaction fee and Pfizer’s legal expenses. Iterum’s CEO, Corey Fishman ...

May 14, 2025 Alnylam drops Covid vaccine patent case against Pfizer, BioNTech for now Biotech ... would be difficult to implement and face legal challenges. The United States and China on Monday ...

Berlaymont has been closely watching the highly anticipated legal ruling on transparency around the European Union’s vaccine deal with pharmaceutical giant Pfizer. Pfizergate is the name of the ...

Shares of Arvinas fell after the biotechnology company ended plans for two Phase 3 trials as part of its collaboration with Pfizer ... and recent challenges in the capital markets have required ...

The pressure to strategize on its pipeline comes as Pfizer prepares for new challenges. The company is bracing for a more than $15 billion loss over the next decade as patents for six major drugs ...

Pfizer Inc (NYSE:PFE) experienced a 6% operational revenue decline in Q1 2025, largely due to lower Paxlovid revenues and changes in Medicare Part D design. The company faces challenges from ...

With $63.6 billion in 2024 revenue and a 7.5% dividend yield, Pfizer remains a powerhouse, leveraging its scale and R&D prowess to address global health challenges. However, since the pandemic ...